SELLAS Life Sciences Group, Inc.
$8.19
-1.7%SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -32.8).
Valuation inputs: P/E -32.8, earnings yield N/A, momentum -1.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -37.9%, ROIC -39.3%).
Profitability stack: net margin 0.0%, ROE -37.9%, ROIC -39.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.5%, momentum -1.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
SELLAS Life Sciences Group, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
SELLAS Life Sciences Group, Inc. Fair Value Envelope
SELLAS Life Sciences Group, Inc. Profit Bridge
Profitability Analysis
SELLAS Life Sciences Group, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
SELLAS Life Sciences Group, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
SELLAS Life Sciences Group, Inc. Street Expectations Map
Wall Street analysts project that SLS stock may decline over the coming 12 months. The consensus 1-year price target stands at 2.80, with estimates ranging from a low of 2.40 to a high of 3.20.
The consensus 1-year price target stands at 2.80, with estimates ranging from a low of 2.40 to a high of 3.20.
Analyst Consensus Analysis
Upside Potential
Significant downside risk. Stock trading well above analyst consensus suggests elevated valuation concerns and potential correction.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Risk-Reward Profile
Unfavorable risk-reward. Downside risk exceeds upside potential. Consider defensive positioning or alternative opportunities.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
Consensus overvaluation: Analysts agree the stock is richly valued with limited upside. Consider booking profits or defensive positioning unless you have contrarian conviction in unrecognized catalysts.
SELLAS Life Sciences Group, Inc. Insider Positioning
During the last 12 months, insiders have purchased $116K worth of SLS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
63.4K
100.81K
0
0.00
+101K
+$101K
9-12 Months
10.0K
14.80K
0
0.00
+15K
+$15K
Top Buyers
Kalin Katherine Bach
Director
$101K
Van Nostrand Robert L
Director
$15K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $116K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
sls Dividend History
Learning Layer
Related Guides
Build conviction on SLS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.